Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $17.16M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 16.15pm 17/08/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 53.0¢ | Day High | 54.0¢ | Day Low | 52.0¢ | |||
| Daily Volume | 40260 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | 52.0¢ | 3517 | 0 | 54.0¢ | 5000 | |
Directors & Senior Management
| Mr. Alexander Bevington Rovira | Independent Non-Executive Director |
| Mr. Benjamin Patrick Donovan | Company Secretary |
| Mr. Karl Jupp | Principal Geologist |
| Mr. Nader El Sayed | Independent Non-Executive Director |
| Mr. Shaun Hardcastle | Independent Non-Executive Chair |
Data source: ADVFN
